Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia

Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in its competition to attract patients to their respective treatments for sickle cell disease (SCD).